Verona Boosts Funds And Becomes Potential Takeover Target
Excitement Builds For COPD Drug Ensifentrine
Executive Summary
The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.
You may also be interested in...
Verona Tops Up Cashpile As Prospective Partners Circle
GSK is looking to do some dealmaking in the respiratory space and fellow UK firm Verona, which has just inked a $400m loan ahead of an expected US approval for its chronic obstructive pulmonary disease candidate ensifentrine, seems a perfect partner.
Verona Stock Soars After $200m Placement For COPD Drug
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.